Cytokinetics, Incorporated (CYTK)

Etorro trading 970x250
Cytokinetics, Incorporated (CYTK) Logo

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Address: 280 East Grand Avenue, South San Francisco, CA, United States, 94080

Cytokinetics, Incorporated News and around…

Latest news about Cytokinetics, Incorporated (CYTK) common stock and company :

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
27 Oct, 2021 Yahoo! Finance

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Cytokinetics (CYTK) Climb 48% to Reach the Level Wall Street Analysts Expect?
27 Oct, 2021 Yahoo! Finance

The consensus price target hints at a 47.8% upside potential for Cytokinetics (CYTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Cytokinetics Announces Preclinical Data for CK-3828136 to Be Presented at the 2021 Medicinal Chemistry Gordon Research Conference
21 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to the discovery and optimization of CK-3828136 (CK-136) will be presented at the 2021 Medicinal Chemistry Gordon Research Conference, taking place in West Dover, VT from October 24, 2021 to October 29, 2021. Session Title: Late-Breaking Topics: First Disclosures of Clinical CandidatesPresentation Title: The Discovery of CK-136, a Selective Cardiac Troponin

Notable Cytokinetics Insider Trades $850K In Company Stock
21 Oct, 2021 Yahoo! Finance

Mark Schlossberg, SVP - Legal And General Counsel at Cytokinetics (NASDAQ:CYTK), made a large buy and sell of company shares on October 19, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Mark Schlossberg exercised options to purchase 19,979 Cytokinetics shares at a price of $7.03 per share for a total of $140,452 on October 19. They then sold their shares on the same day in the open market. They sold at a price of $35.74

Cytokinetics to Announce Third Quarter Results on November 3, 2021
20 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the ho

Hedge Funds Are Crazy About Cytokinetics, Inc. (CYTK)
18 Oct, 2021 Yahoo! Finance

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

Add Up The Pieces: SLYG Could Be Worth $105
18 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P 600 Small Cap Growth ETF (SLYG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $104.62 per unit.

How Much Upside is Left in Cytokinetics (CYTK)? Wall Street Analysts Think 37%
11 Oct, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Cytokinetics (CYTK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Where Cytokinetics Stands With Analysts
08 Oct, 2021 FinancialContent

Over the past 3 months, 6 analysts have published their opinion on Cytokinetics (NASDAQ:CYTK) stock. These analysts are typically ...

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Expert Ratings For Cytokinetics
07 Oct, 2021 FinancialContent

Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Notable ETF Outflow Detected - XBI, CYTK, CCXI, SRPT
07 Oct, 2021 FinancialContent

Symbols mentioned in this story: XBI, CYTK, CCXI, SRPT Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

First Week of CYTK May 2022 Options Trading
07 Oct, 2021 FinancialContent

Investors in Cytokinetics Inc (CYTK) saw new options begin trading this week, for the May 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
07 Oct, 2021 FinancialContent

Upgrades For State Street Corporation (NYSE:STT), Wolfe Research upgraded the previous rating of Peer Perform to ...

Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv Mecarbil and Provides Updates on Cardiovascular Pipeline at Today’s Analyst & Investor Day
07 Oct, 2021 Yahoo! Finance

SEQUOIA-HCM: Phase 3 Trial Design Design of SEQUOIA-HCM, a Phase 3 randomized, placebo-controlled, double-blind, multi-center clinical trial designed to evaluate aficamten in patients with symptomatic oHCM on background medical therapy for 24 weeks. Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and Support Clinical Trial Design Announced for SEQUOIA-HCM, Phase 3 Clinical Trial of Aficamten Ex

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Cramer Weighs In On Cytokinetics, LegalZoom And Matterport
29 Sep, 2021 FinancialContent

On CNBC's "Mad Money Lightning Round," Jim Cramer said Cytokinetics, Inc. (NASDAQ: CYTK) is a very good spec. Big pharma ...

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals
28 Sep, 2021 FinancialContent
Noteworthy ETF Inflows: XBI, XLRN, ALEC, CYTK
24 Sep, 2021 FinancialContent

Symbols mentioned in this story: XBI, XLRN, ALEC, CYTK Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

Cytokinetics to Host Analyst & Investor Day on October 7, 2021
23 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Analysts Forecast 16% Upside For IJR
16 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Small-Cap ETF (IJR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $127.18 per unit.

Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
12 Sep, 2021 FinancialContent
Noteworthy Friday Option Activity: IIPR, TWTR, CYTK
10 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Innovative Industrial Properties Inc (IIPR), where a total volume of 1,234 contracts has been traded thus far today, a contract volume which is representative of approximately 123,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 86.8% of IIPR's average daily trading volume over the past month, of 142,145 shares..

Cytokinetics to Participate in September Investor Conferences
08 Sep, 2021 FinancialContent
Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting
07 Sep, 2021 FinancialContent
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep, 2021 FinancialContent

Cytokinetics, Incorporated (CYTK) is a NASDAQ Common Stock listed in , ,

970x250